Claims for Patent: 7,655,466

Summary for Patent: 7,655,466

Title:	Production process for munant
Abstract:	The invention provides a production process for a high-frequent random mutant of an object exogenous gene, wherein a recombinant expression vector in which a eukaryote promoter, an exogenous DNA sequence, an intron enhancer and 3\'HS3/4 enhancer are linked is introduced and expressed in an animal cell.
Inventor(s):	Azuma; Takachika (Noda-shi, Chiba, JP)
Assignee:	Azuma; Takachika (Chiba, JP) Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:	10/481,742
Patent Claims:	1. A process for producing random mutants of DNA encoding an exogenous polypeptide comprising: (A) introducing into an animal cell a DNA construct comprising the following (i)-(iv): (i) a promoter; (ii) DNA encoding an exogenous polypeptide provided that said DNA encoding an exogenous polypeptide does not encode an immunoglobulin; (iii) an intron enhancer; and (iv) an enhancer comprising at least one of HS3b and HS4, in a DNaseI sensitive region; and (B) culturing the resulting animal cell whereby during said culturing said enhancer comprising at least one of HS3b and HS4 acts to produce random mutants of DNA encoding the exogenous polypeptide in the animal cell. 2. The process according to claim 1, wherein the (iv) enhancer further comprises HS1 and HS2. 3. The process according to claim 1, wherein the (iv) enhancer comprises the nucleotide sequence of SEQ ID NO: 1 and SEQ ID NO: 2. 4. The process according to claim 2, wherein the (iv) enhancer comprises HS1, HS2, HS3b and HS4. 5. The process according to claim 1, wherein the (i) promoter is a V.sub.H promoter; and the (iv) enhancer comprises the nucleotide sequences of SEQ ID NOs: 1 and 2. 6. The process according to claim 4, wherein the DNA construct is pvehc3'EHS3b/4. 7. The process according to claim 1, wherein the animal cell is a B cell line animal cell. 8. A method for obtaining mutants of an exogenous polypeptide comprising: producing random mutants of DNA encoding an exogenous polypeptide by a method comprising: (1) introducing into an animal cell a DNA construct comprising the following (a)-(d): (a) a promoter; (b) DNA encoding an exogenous polypeptide provided that said DNA encoding an exogenous polypeptide does not encode an immunoglobulin; (c) an intron enhancer; and (d) an enhancer comprising at least one of HS3b and HS4, in a DNaseI sensitive region; (2) culturing the resulting animal cell whereby during said culturing said enhancer comprising at least one of HS3b and HS4 acts to produce random mutants of DNA encoding the exogenous polypeptide in the animal cell; and (3) expressing said random mutants of DNA encoding the exogenous polypeptide in the animal cell so as to obtain said mutants of said exogenous polypeptide. 9. A DNA construct for producing mutants of an exogenous polypeptide, comprising the following (i)-(iv): (i) a promoter; (ii) DNA encoding an exogenous polypeptide provided that said DNA encoding an exogenous polypeptide does not encode an immunoglobulin; (iii) an intron enhancer; and (iv) an enhancer comprising at least one of HS3b and HS4, in a DNaseI sensitive region. 10. The DNA construct according to claim 9, wherein the (iv) enhancer further comprises HS1 and HS2. 11. The DNA construct according to claim 9, wherein the (iv) enhancer comprises the nucleotide sequence of SEQ ID NO: 1 and 2. 12. The DNA construct according to claim 9, wherein the (iv) enhancer comprises HS1, HS2, HS3b and HS4. 13. The DNA construct according to claim 9, wherein the (i) promoter is a V.sub.H promoter; and the (iv) enhancer comprises the nucleotide sequence of SEQ ID NOs: 1 and 2. 14. The DNA construct according to claim 9, wherein the DNA construct is pvehc3'EHS3b/4. 15. A kit for producing random mutants of DNA encoding an exogenous polypeptide or for producing an expression product thereof, comprising a vector comprising: (i) a promoter; (ii) an insertion site for insertion of DNA encoding an exogenous polypeptide; (iii) an intron enhancer; and (iv) an enhancer comprising at least one of HS3b and HS4, in a DNaseI sensitive region. 16. The kit according to claim 15, wherein the (iv) enhancer further comprises HS1 and HS2.

Details for Patent 7,655,466

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-06-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-06-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-06-25